Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UHB6: Variant p.Leu25Ile

LIM domain and actin-binding protein 1
Gene: LIMA1
Feedback?
Variant information Variant position: help 25 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Leucine (L) to Isoleucine (I) at position 25 (L25I, p.Leu25Ile). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help Genetic variations in LIMA1 influence low density lipoprotein cholesterol (LDL-C) variability and contribute to the low density lipoprotein cholesterol level quantitative trait locus 8 (LDLCQ8) [MIM:618079]. Additional information on the polymorphism described.
Variant description: help Correlated with lower plasma levels of low-density lipoprotein cholesterol; reduces protein stability. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 25 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 759 The length of the canonical sequence.
Location on the sequence: help PFNRRQWTSLSLRVTAKELS L VNKNKSSAIVEIFSKYQKAA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         PFNRRQWTSLSLRVTAKELSLVNKNKSSAIVEIFSKYQKAA

Mouse                         PFNRRQWTSLSLRVTAKELSLVNKNKSSAIVEIFSKYQKAA

Rat                           PFNRRQWTSLSLRVTAKELSLVNKNKSSTIVEIFSKYQKAA

Pig                           PFNRQQWTSLSLRVTAKELSLVNKNKSSAIVEIFSKYQKAA

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 759 LIM domain and actin-binding protein 1
Modified residue 15 – 15 Phosphoserine
Alternative sequence 1 – 302 Missing. In isoform 3.
Alternative sequence 1 – 160 Missing. In isoform Alpha and isoform 5.



Literature citations
A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption.
Zhang Y.Y.; Fu Z.Y.; Wei J.; Qi W.; Baituola G.; Luo J.; Meng Y.J.; Guo S.Y.; Yin H.; Jiang S.Y.; Li Y.F.; Miao H.H.; Liu Y.; Wang Y.; Li B.L.; Ma Y.T.; Song B.L.;
Science 360:1087-1092(2018)
Cited for: VARIANT ILE-25; CHARACTERIZATION OF VARIANT ILE-25; INTERACTION WITH NPCL1; POLYMORPHISM;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.